Exodus Point Capital Management, LP Vaxart, Inc. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.56 - $1.41 $43,925 - $110,598	78,439 New	78,439 $102,000
Q4 2022 Feb 13, 2023	SELL	$0.75 - $2.24 $236,475 - $706,272	-315,300 Reduced 75.31%	103,363 $99,000
Q3 2022 Nov 10, 2022	BUY	$2.09 - $4.5 $753,190 - $1.62 Million	360,378 Added 618.3%	418,663 $913,000
Q2 2022 Aug 19, 2022	BUY	$2.7 - $5.28 $157,369 - $307,744	58,285 New	58,285 $204,000
Q4 2021 Feb 11, 2022	SELL	$5.77 - $7.96 $251,571 - $347,056	-43,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $290,812 - $427,280	43,600 New	43,600 $347,000
Q4 2020 Feb 16, 2021	SELL	$3.5 - $7.98 $88,917 - $202,731	-25,405 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.78 - $16.97 $121,435 - $431,122	25,405 New	25,405 $169,000
Q2 2020 Aug 14, 2020	SELL	$1.68 - $8.85 $27,048 - $142,485	-16,100 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.34 - $2.87 $5,474 - $46,207	16,100 New	16,100 $28,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.